Abstract
Adrenal cortical carcinoma is a rare but interesting endocrine tumor. Its diagnosis is usually straightforward using morphologic assessment and supplemental immunohistochemistry. However, diagnostically challenging cases exist and pathologic evaluation would benefit from the availability of adjunctive molecular testing. Here, the relevant molecular pathology of adrenal cortical tumors is reviewed with special reference to those methods (e.g., DNA microarrays) that hold promise for improved diagnosis and prognosis, and prediction of therapeutic response.
Similar content being viewed by others
References
Bovio S, Cataldi A, Reimondo G, et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest 29:298–302, 2006.
Vierhapper H. Adrenocortical tumors: clinical symptoms and biochemical diagnosis. Eur J Radiol 41:88–94, 2002.
Stratakis CA. Genetics of adrenocortical tumors: gatekeepers, landscapers and conductors in symphony. Trends Endocrinol Metab 14:404–410, 2003.
Kirschner LS. Emerging treatment strategies for adrenocortical carcinoma: a new hope. J Clin Endocrinol Metab 91:14–21, 2006.
Schteingart DE, Doherty GM, Gauger PG, et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 12:667–680, 2005.
McNicol AM, Struthers AL, Nolan CE, et al. Proliferation in adrenocortical tumors: correlation with clinical outcome and p53 status. Endocr Pathol 8:29–36, 1997.
Nakazumi H, Sasano H, Iino, K, Ohashi Y, Orikasa S. Expression of cell cycle inhibitor p27 and Ki-67 in human adrenocortical neoplasms. Mod Pathol 11:1165–1170, 1998.
Terzolo M, Boccuzzi A, Bovio S, et al. Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumors. Urology 57:176–182, 2001.
Iino K, Sasano H, Yabuki N, et al. DNA topoisomerase II alpha and Ki-67 in human adrenocortical neoplasms: a possible marker of differentiation between adenomas and carcinomas. Mod Pathol 10:901–907, 1997.
Giordano TJ, Thomas DG, Kuick R, et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol 162:521–531, 2003.
Erickson LA, Jin L, Sebo TJ, et al. Pathologic features and expression of insulin-like growth factor-2 in adrenocortical neoplasms. Endocr Pathol 12:429–435, 2001.
Dohna M, Reincke M, Mincheva A, et al. Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high-level amplifications. Genes Chromosomes. Cancer 28:145–152, 2000.
Kjellman M, Kallioniemi OP, Karhu R, et al. Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. Cancer Res 56:4219–4223, 1996.
Sidhu S, Marsh DJ, Theodosopoulos G, et al. Comparative genomic hybridization analysis of adrenocortical tumors. J Clin Endocrinol Metab 87:3467–3474, 2002.
Zhao J, Roth J, Bode-Lesniewska B, et al. Combined comparative genomic hybridization and genomic microarray for detection of gene amplifications in pulmonary artery intimal sarcomas and adrenocortical tumors. Genes chromosomescancer 34:48–57, 2002.
Boulle N, Logie A, Gicquel C, et al. Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. J Clin Endocrinol Metab 83:1713–1720, 1998.
Fottner C, Hoeflich A, Wolf E, et al. Role of the insulin-like growth factor system in adrenocortical growth control and carcinogenesis. Horm Metab Res 36:397–405, 2004.
Gao ZH, Suppola S, Liu J, et al. Association of H19 promoter methylation with the expression of H19 and IGF II genes in adrenocortical tumors. J Clin Endocrinol Metab 87:1170–1176, 2002.
Gicquel C, Bertagna X, Gaston V, et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res 61:6762–6767, 2001.
Gicquel C, Bertagna X, Schneid H, et al. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J Clin Endocrinol Metab 78:1444–1453, 1994.
Gicquel C, Raffin-Sanson MI, Gaston V, et al. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J Clin Endocrinol Metab 82:2559–2565, 1997.
Ilvesmaki V, Kahri AI, Miettinen PJ, et al. Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas. J Clin Endocrinol Metab 77:852–858, 1993.
Liu J, Kahri AI, Heikkila P, et al. H19 and insulin-like growth factor-II gene expression in adrenal tumors and cultured adrenal cells. J Clin Endocrinol Metab 80:492–496, 1995.
Liu J, Kahri AI, Heikkila P, et al. Ribonucleic acid expression of the clustered imprinted genes, p57KIP2, insulin-like growth factor II, and H19, in adrenal tumors and cultured adrenal cells. J Clin Endocrinol Metab 82:1766–1771, 1997.
Logie A, Boulle N, Gaston V, et al. autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line. J Mol Endocrinol 23:23–32, 1999.
Weber MM, Fottner C, Wolf E. The role of the insulin-like growth factor system in adrenocortical tumourigenesis. Eur J Clin Invest 30(Suppl 3):69–75, 2000.
Sameshima Y, Tsunematsu Y, Watanabe S, et al. Detection of novel germ-line p53 mutations in diverse-cancer-prone families identified by selecting patients with childhood adrenocortical carcinoma. J Natl Cancer Inst 84: 703–707, 1992.
Barzon L, Chilosi M, Fallo F, et al. Molecular analysis of CDKN1C and TP53 in sporadic adrenal tumors. Eur J Endocrinol 145: 207–212, 2001.
Kobayashi H, Usui T, Fukata J, et al. Mutation analysis of Gsalpha, adrenocorticotropin receptor and p53 genes in Japanese patients with adrenocortical neoplasms: including a case of Gsalpha mutation. Endocr J 47:461–466, 2000.
Latronico AC, Pinto EM, Domenice S, et al. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J Clin Endocrinol Metab 86:4970–4973, 2001.
Lin SR, Lee YJ, Tsai JH. Mutations of the p53 gene in human functional adrenal neoplasms. J Clin Endocrinol Metab 78:483–491, 1994.
Ohgaki H, Kleihues P, Heitz PU. p53 mutations in sporadic adrenocortical tumors. Int J Cancer 54:408–410 1993.
Olivier M, Goldgar DE, Sodha N, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 63:6643–6650, 2003.
Pinto EM, Billerbeck AE, Fragoso MC, et al. Deletion mapping of chromosome 17 in benign and malignant adrenocortical tumors associated with the Arg337His mutation of the p53 tumor suppressor protein. J Clin Endocrinol Metab 90:2976–2981, 2005.
Pinto EM, Billerbeck AE, Villares MC, et al. Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors. Arq Bras Endocrinol Metabol 48:647–650, 2004.
Reincke M, Karl M, Travis WH, et al. p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J Clin Endocrinol Metab 78:790–794, 1994.
Reincke M, Wachenfeld C, Mora P, et al. p53 mutations in adrenal tumors: Caucasian patients do not show the exon 4 “hot spot” found in Taiwan. J Clin Endocrinol Metab 81:3636–3638, 1996.
Sandrini F, Villani DP, Tucci S, et al. Inheritance of R337H p53 gene mutation in children with sporadic adrenocortical tumor. Horm Metab Res 37:231–235, 2005.
Sidhu S, Martin E, Gicquel C, et al. Mutation and methylation analysis of TP53 in adrenal carcinogenesis. Eur J Surg Oncol 31:549–554, 2005.
Varley JM, McGown G, Thorncrolt M, et al. Are there low-penetrance TP53 alleles? Evidence from childhood adrenocortical tumors. Am J Hum Genet 65:995–1006, 1999.
Wagner J, Portwine C, Rabin K, et al. High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst 86:1707–1710, 1994.
Libe R, Bertherat J. Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. Eur J Endocrinol 153:477–487, 2005.
Heppner C, Reincke M, Agarwal SK, et al. MEN1 gene analysis in sporadic adrenocortical neoplasms. J Clin Endocrinol Metab 84:216–219, 1999.
Schulte KM, Heinze M, Mengel M, et al. MEN 1 gene mutations in sporadic adrenal adenomas. Hum Genet 105:603–610, 1999.
Schulte KM, Mengel M, Heinze M, et al. Complete sequencing and messenger ribonucleic acid expression analysis of the MEN I gene in adrenal cancer. J Clin Endocrinol Metab 85:441–448, 2000.
Bertherat J, Groussin L, Sandrini F, et al. Molecular and functional analysis of PRKARIA and its locus (17q22–24) in sporadic adrenocortical tumors: 17qlosses, somatic mutations, and protein kinase A expression and activity. Cancer Res 63:5308–5319, 2003.
Bossis I, Vourtetakis A, Bei T, et al. Protein kinase A and its role in human neoplasia: the Carney complex paradigm. Endocr Relat Cancer 11:265–280, 2004.
Groussin L, Jullian E, Perlemoine K, et al. Mutations of the PRKAR1A gene in Cushing's syndrome due to sporadic primary pigmented nodular adrenocortical disease. J Clin Endocrinol Metab 87:4324–4329, 2002.
Libe R, Mantovani G, Bondioni S, et al. Mutational analysis of PRKAR1A and Gs(alpha) in sporadic adrenocortical tumors. Exp Clin Endocrinol Diabetes 113:248–251, 2005.
Tissier F, Cavard C, Groussin L, et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res 65:7622–7627, 2005.
Ciampi R, Nikiforov YE. Alterations of the BRAF gene in thyroid tumors. Endocr Pathol 16:163–172, 2005.
Ciampi R, Zhu Z, Nikiforov YE. BRAF copy number gains in thyroid tumors detected by fluorescence in situ hybridization. Endocr Pathol 16:99–105, 2005.
Ciampi R, Knauf JA, Kerler R, et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 115:94–101, 2005.
Lakhani SR, Ashworth A. Microarray and histopathological analysis of tumours: the future and the past? Nat Rev Cancer 1:151–157, 2001.
Mischel PS, Cloughesy TF, Nelson SF. DNA-microarray analysis of brain cancer: molecular classification for therapy. Nat Rev Neurosci 5:782–792, 2004.
Snijders AM, Meijer GA, Brakenhoff RH, et al. Microarray techniques in pathology: tool or toy? Mol Pathol 53:289–294, 2000.
Alizadeh AA, Ross DT, Perou CM, et al. Towards a novel classification of human malignancies based on gene expression patterns. J Pathol 195:41–52, 2001.
Giordano TJ, Gene expression profiling of endocrine tumors using DNA microarrays: progress and promise. Endocr Pathol 14:107–116, 2003.
de Fraipont F, El Atifi M, Cherradi N, et al. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab 90:1819–1829, 2005.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Giordano, T.J. Molecular pathology of adrenal cortical tumors: Separating adenomas from carcinomas. Endocr Pathol 17, 355–364 (2006). https://doi.org/10.1007/s12022-006-0007-z
Issue Date:
DOI: https://doi.org/10.1007/s12022-006-0007-z